Cargando…

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity

T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion. Tim-3 has also been identified in various solid tumors. However, the role of Tim-3 expression on blast cells in acute myeloid leukemia (AML) is not well understood....

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Liangjing, Xu, Jinge, Ma, Shoubao, Li, Xiaoli, Zhu, Mingqing, Chen, Suning, Han, Yue, Tang, Xiaowen, Fu, Zhengzheng, Qiu, Huiying, Yu, Jianhua, Wu, Depei, Wu, Xiaojin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731937/ https://www.ncbi.nlm.nih.gov/pubmed/29254227 http://dx.doi.org/10.18632/oncotarget.22141

Ejemplares similares

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes
por: Hong, Jian, et al.
Publicado: (2022)

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
por: Dama, Paola, et al.
Publicado: (2019)

Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients
por: Yang, Bingyu, et al.
Publicado: (2018)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Chemotherapy Promotes Release of Exosomes Which Upregulate Cholesterol Synthesis and Chemoresistance in AML Blasts
por: Hong, Chang-Sook, et al.
Publicado: (2021)

CD19/CD22 dual‐targeting chimeric antigen receptor T‐cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B‐cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein–Barr virus viremia after transplantation
por: Li, Shijia, et al.
Publicado: (2023)

The Clinical Value of Procalcitonin in the Neutropenic Period After Allogeneic Hematopoietic Stem Cell Transplantation
por: Shan, Meng, et al.
Publicado: (2022)

EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia
por: Wang, Xiuli, et al.
Publicado: (2013)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
por: Zhang, Keyuan, et al.
Publicado: (2023)

P378: CHEMO-FREE TREATMENT OF VAF INDUCE A EARLY AND DEEP MOLECULAR RESPONSEIN IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A PROSPECTIVE, SINGLE ARM, PHASE II STUDY
por: LI, Mengyun, et al.
Publicado: (2023)

Identification and validation of a 7-genes prognostic signature for adult acute myeloid leukemia based on aging-related genes
por: Ke, Peng, et al.
Publicado: (2023)

TIM-3 and TIM-1 Could Regulate Decidual γδTCR Bright T Cells during Murine Pregnancy
por: Nörenberg, Jasper, et al.
Publicado: (2019)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase
por: Cui, Qingya, et al.
Publicado: (2022)

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021)

Recurrent Novel P2RY8/IGH Translocations in B-Lymphoblastic Leukemia/Lymphoma
por: Fang, Yanglan, et al.
Publicado: (2022)

Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia
por: Tang, Yaqiong, et al.
Publicado: (2015)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

High stearic acid diet modulates gut microbiota and aggravates acute graft-versus-host disease
por: Yang, Bingyu, et al.
Publicado: (2021)

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
por: Rakova, Jana, et al.
Publicado: (2021)

Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
por: Liu, Shuangzhu, et al.
Publicado: (2018)

Comparison of Haploidentical Hematopoietic Stem Cell Transplant With or Without Unrelated Cord Blood Infusion in Severe Aplastic Anemia: Outcomes of a Multicenter Study
por: Lei, Meiqing, et al.
Publicado: (2022)

Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML
por: Sargent, J M, et al.
Publicado: (2001)

Expression of CD200 on AML blasts directly suppresses memory T-cell function
por: Coles, S J, et al.
Publicado: (2012)

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
por: Sun, Yingxin, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience
por: Shen, Yaoyao, et al.
Publicado: (2021)

CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
por: Yao, Zhenzhen, et al.
Publicado: (2023)

Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes
por: Asayama, Toshio, et al.
Publicado: (2017)

Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy
por: Jin, Jing, et al.
Publicado: (2018)

Comparable Outcomes and Health-Related Quality of Life for Severe Aplastic Anemia: Haploidentical Combined With a Single Cord Blood Unit vs Matched Related Transplants
por: Lei, Meiqing, et al.
Publicado: (2022)

Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study
por: Li, Weiyang, et al.
Publicado: (2020)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
por: Holicek, Peter, et al.
Publicado: (2023)

ILC1s Control Leukemia Stem Cell Fate and Limit Development of AML
por: Li, Zhenlong, et al.
Publicado: (2022)

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
por: Chen, Suning, et al.
Publicado: (2022)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7)
por: Karkuzhali, Ponnuswamy, et al.
Publicado: (2013)

Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment
por: Bunaciu, Rodica P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bbejkblac0d7hguqudgqs69gll